Northern Trust Corp raised its stake in shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) by 640.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 297,152 shares of the biotechnology company’s stock after buying an additional 257,030 shares during the quarter. Northern Trust Corp owned about 1.06% of Conatus Pharmaceuticals worth $1,712,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Bank of Montreal Can purchased a new position in shares of Conatus Pharmaceuticals in the second quarter worth $109,000. FNY Partners Fund LP raised its stake in shares of Conatus Pharmaceuticals by 98.0% in the second quarter. FNY Partners Fund LP now owns 19,800 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 9,800 shares during the last quarter. State of Wisconsin Investment Board purchased a new position in shares of Conatus Pharmaceuticals in the second quarter worth $115,000. Strs Ohio purchased a new position in shares of Conatus Pharmaceuticals in the second quarter worth $153,000. Finally, Eagle Global Advisors LLC purchased a new position in shares of Conatus Pharmaceuticals in the second quarter worth $156,000. Institutional investors and hedge funds own 36.95% of the company’s stock.
Shares of Conatus Pharmaceuticals Inc (NASDAQ CNAT) opened at $4.07 on Tuesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.69 and a current ratio of 2.69. Conatus Pharmaceuticals Inc has a fifty-two week low of $1.81 and a fifty-two week high of $9.40.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.13) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.08). Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. The firm had revenue of $9.57 million during the quarter, compared to the consensus estimate of $16.06 million. During the same period in the previous year, the firm earned ($0.31) EPS. equities research analysts anticipate that Conatus Pharmaceuticals Inc will post -0.65 EPS for the current fiscal year.
Several research analysts have recently weighed in on the company. Zacks Investment Research upgraded Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 3rd. HC Wainwright restated a “buy” rating and issued a $17.00 price target (down previously from $18.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, November 2nd. Finally, Seaport Global Securities restated a “buy” rating and issued a $16.00 price target on shares of Conatus Pharmaceuticals in a research note on Friday, October 6th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $16.00.
ILLEGAL ACTIVITY NOTICE: “Northern Trust Corp Buys 257,030 Shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT)” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/12/12/conatus-pharmaceuticals-inc-cnat-position-lifted-by-northern-trust-corp.html.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.